Cegieła, Urszula.
Urszula Cegieła
VIAF ID: 161819477 (Personal)
Permalink: http://viaf.org/viaf/161819477
Preferred Forms
-
- 100 1 _ ‡a Cegieła, Urszula
-
- 100 0 _ ‡a Urszula Cegieła
4xx's: Alternate Name Forms (3)
Works
Title | Sources |
---|---|
Alendronate prevents development of the skeletal changes induced by azathioprine in rats | |
Changes and their regression in the osseous system in rats after administering a cytostatic drug inhibiting tumor cell division in the phase of DNA synthesis | |
Effect of administration of alendronate sodium and retinol on the mechanical properties of the femur in ovariectomized rats. | |
[Effect of cyclophosphamide on bone remodeling in rats] | |
Effects of 6-mercaptopurine | |
Effects of catecholamines on the intramedullary pressure in the femur in rats with prednisolone-induced osteoporosis | |
Effects of diosgenin on the skeletal system in rats with experimental type 1 diabetes | |
Effects of fenoterol on the skeletal system depend on the androgen level | |
Effects of propranolol on the development of glucocorticoid-induced osteoporosis in male rats | |
Effects of retinol on development of osteopenic changes induced by bilateral ovariectomy in rats. | |
Exercise prevented the lansoprazole-induced reduction of anti-osteoporotic efficacy of alendronate in androgen deficiency rats | |
Farmakologia w zarysie | |
Fenoterol did not enhance glucocorticoid-induced skeletal changes in male rats | |
Kompendium farmakologii | |
Medical pharmacology at a glance. | |
Phloridzin, an Apple Polyphenol, Exerted Unfavorable Effects on Bone and Muscle in an Experimental Model of Type 2 Diabetes in Rats | |
Proton pump (H+/K+-ATPase) inhibitors weaken the protective effect of alendronate on bone mechanical properties in estrogen-deficient rats | |
Raloxifene does not affect the changes in bone histomorphometric parameters induced by low dose tacrolimus in male rats | |
Raloxifene similarly affects the skeletal system of male and ovariectomized female rats. | |
Wpływ formestanu na układ kostny u owariektomizowanych i kontrolnych szczurów. | |
Zapobieganie zaburzeniom przebudowy kości u szczurów po stosowaniu leków immunosupresyjnych |